A Trace ‘Tides Primer: Understanding a synthetic analogue of growth hormone releasing hormone

By: Laura Mildon

CJC-1295 is a synthetic peptide analogue of growth hormone-releasing hormone, or GHRH. An analogue is a molecule designed with structural similarities to another molecule, along with deliberate modifications. CJC-1295 research examines peptide engineering, albumin binding, and hormonal signaling.

The original compound described in the development literature includes an albumin-binding modification commonly called DAC. This article focuses on that compound and explains why similarly named materials should be identified separately. Published findings do not establish a benefit or intended application for a commercial research product.

What GHRH means

GHRH is a signaling peptide involved in regulation of growth hormone secretion from the pituitary gland. Growth hormone and insulin-like growth factor 1, or IGF-1, are distinct molecules measured in some CJC-1295 studies. CJC-1295 is an analogue of the releasing signal, rather than growth hormone itself.

Chemical identity

These values describe the molecular entity in the cited PubChem record. Salt counterions, hydration, and different chemical modifications require separate identification. A database identifier does not verify the identity or purity of a supplied material.

PubChem identity and chemical structure

What DAC means

DAC stands for drug affinity complex. In this context, it refers to a chemical modification designed to form a covalent bond with albumin, a protein abundant in blood. A covalent bond links atoms by sharing electrons. Researchers investigated whether albumin attachment could change the peptide’s persistence while preserving receptor activity.

The modification is part of the compound’s chemical identity. It cannot be treated as an optional label when interpreting a study.

History and research origins

CJC-1295 emerged from ConjuChem’s work on albumin-binding peptide technology. In 2005, Jetté and colleagues published research identifying it as a modified growth hormone-releasing factor analogue. Their study investigated albumin conjugates and receptor activity in laboratory systems and rats.

This publication documents an early development milestone. It should not be presented as an exact date of first synthesis. Subsequent papers examined hormonal measurements in early human studies, extending the research beyond the initial experimental models.

Jetté and colleagues in Endocrinology 2005

Selected published research

CJC-1295 is not FDA-approved as a medicine. The studies below address defined experimental questions. Early human research is not equivalent to approval or proof of long-term safety and effectiveness.

Albumin binding and receptor activity in 2005

Jetté and colleagues examined modified GHRH peptides that could bind albumin. They investigated whether the resulting conjugates retained activity at the GHRH receptor and measured hormonal responses in rats.

The study supported further investigation of the DAC-containing compound. It does not establish that another peptide without the same modification behaves similarly, or that an uncharacterized commercial preparation reproduces the results.

Read the original albumin conjugate study

Hormonal measurements in early clinical research in 2006

Teichman and colleagues reported two randomized, placebo-controlled, double-blind studies in healthy adults. They evaluated the DAC-containing analogue’s pharmacokinetics—how the compound behaves over time—and changes in growth hormone and IGF-1 measurements.

The investigators observed prolonged changes in these hormonal markers. Such measurements show biological activity under study conditions; they do not establish a disease-treatment, body-composition, recovery, or longevity benefit. The studies were limited in size and duration.

Teichman and colleagues in The Journal of Clinical Endocrinology and Metabolism 2006

Patterns of hormone secretion in 2006

Ionescu and Frohman examined growth hormone secretion patterns after exposure to the long-acting analogue in a small study of healthy men. They reported that pulsatile secretion persisted despite sustained stimulation.

Pulsatile means that secretion occurs in peaks rather than at a constant rate. This finding addresses secretion patterns and their relationship to IGF-1 measurements. It does not establish that the intervention is physiologically equivalent to normal regulation or that long-term outcomes are favorable.

Ionescu and Frohman in The Journal of Clinical Endocrinology and Metabolism 2006

Clarifying the name without DAC

The marketplace also uses “CJC-1295 without DAC” for modified GHRH peptides lacking the albumin-binding unit, often described as modified GRF 1–29. FDA’s assessment distinguishes DAC-containing and non-DAC substances, along with their salt forms.

The long-acting DAC compound and a non-DAC peptide are different molecular entities. Their formulas, structures, and research findings should not be combined under a single chemical profile. The exact sequence, terminal groups, and presence of the albumin-binding unit must be specified.

FDA assessment distinguishing CJC-1295-related substances

Molecular structure

A molecular formula lists atom counts; it does not uniquely determine a peptide’s structure. The PubChem record linked above provides a two-dimensional depiction of the DAC-containing molecular entity, including its chemical modification. This is an atom-connectivity diagram, not an experimentally established fixed three-dimensional shape.

What remains unresolved

The selected research demonstrates that the specified compound can affect hormonal measurements. It does not resolve long-term safety, clinical effectiveness, or whether an independently supplied material matches the compound studied.

Interpretation also depends on chemical identity. Findings for the DAC-containing analogue cannot automatically be applied to a non-DAC peptide, a salt with an incompletely specified composition, or a blend containing other compounds.

Regulatory context

FDA identifies CJC-1295 among bulk substances for compounding that may present significant safety risks. Its notice highlights concerns about immune responses, peptide-related impurities, and characterization of the active ingredient. It also identifies serious adverse events associated with CJC-1295, including increased heart rate and systemic vasodilatory reactions, and notes that available clinical data are limited.

A systemic vasodilatory reaction involves widening of blood vessels across the body. Reports of associated events require careful interpretation; they do not establish that every reported event was caused by the compound. The limited evidence nevertheless leaves material safety questions unanswered.

FDA’s compounding review addresses particular substances and proposed drug products. Research labeling and advisory committee discussion do not establish FDA approval, clinical safety, or permission for another intended use.

FDA notice on CJC-1295 and compounding safety risks

Research and regulatory sources checked October 13, 2026.

DISCLAIMER: These statements are for research purposes only and have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Why choose Trace 'Tides? 

Because trust starts with real people, clear answers, and quality you can verify. We have a certified peptide specialist on staff, a phone number that connects you with a real human, and a physical location you can visit by appointment. Call or text us—we’re delighted to answer your questions and address your concerns. We also make checkout straightforward by accepting credit cards, without asking you to use cryptocurrency or connect your bank account to an unfamiliar payment app. And every peptide we sell is tested for purity and endotoxins by licensed U.S. laboratories, so you can choose your research peptides with confidence.